Pulse Biosciences Inc PLSE 深 滬
等待開盤 12-17 09:30:00 美东时间
14.23
+0.100
+0.71%
華盛通- 最 高14.39
- 今 開14.00
- 成交量 30.96万股
- 最 低 13.97
- 昨 收 14.13
- 總市值 9.58亿
- 52周最高 25.00
- 市盈率 靜 --
- 換手率 0.46%
- 52周最低 12.56
- 委 比 -75.61%
- 總股本 6729.58万
- 歷史最高 45.82
- 量 比 1.52
- 振 幅 2.97%
- 歷史最低 1.18
- 每 手 1
- 風險率 1.97%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pulse Biosciences Teams Up With MD Anderson To Test New Thyroid Cancer Treatment In FDA-Approved Study
Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or
12-09 20:10
Pulse Biosciences Updates Investors on Product Advancements
Pulse Biosciences ( ($PLSE) ) just unveiled an announcement. On November 13, 20...
11-13 22:48
Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
Pulse Biosciences Announces Enrollment Of First Patient In NANOCLAMP AF Study For Treatment Of Atrial Fibrillation
First U.S. Surgical Treatments with PFA Clamp for Patients with Atrial Fibrillation During Concomitant Surgical ProcedurePulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology
10-24 19:01
Pulse Biosciences Reveals Promising Study Results
Pulse Biosciences ( ($PLSE) ) has provided an announcement. On October 10, 2025...
10-10 21:28
Pulse Biosciences Announces Late-Breaking Clinical Study Results From nPulse Cardiac Surgical System First-In-Human Feasibility Study At 39th European Association For Cardio-Thoracic Surgery Annual Meeting
Successfully treated atrial fibrillation (AF) in initial 30 patients with the nPulse™ Cardiac Surgical SystemPulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using
10-10 19:02
7点！医械早播报-9/11
（来源：医疗器械创新网） 01 监管政策与招投标 （一）监管政策 三部门联合建立常态化巡回医疗制度，82 支医疗队赴基层 国家卫健委、国家中医药局、国家疾控局联...
09-11 07:00
Pulse Biosciences Begins First Study Using Nanosecond PFA Tech To Treat Benign Thyroid Nodules
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the first successful procedures
09-02 19:05
Pulse Biosciences Announced A New Publication In The Journal Thyroid, The First-in-human Clinical Feasibility Study Demonstrates The Effectiveness Of Ablation Of Benign Thyroid Nodules Using Nanosecond Pulsed Field Ablation (nsPFA) Energy
The study was designed to assess the ability of nsPFA energy to provide a safe and effective option for the treatment of symptomatic benign thyroid nodules with minimal side effects. The study was conducted by Professor
08-26 19:05
Pulse Biosciences shares are trading lower after the company reported a Q2 EPS miss.
Pulse Biosciences shares are trading lower after the company reported a Q2 EPS ...
08-13 22:30
